Jiangsu Hengrui Pharmaceuticals dividend and valuation
Valuation
Jiangsu Hengrui Pharmaceuticals paid ¥0.20 per share in dividends over the last 12 months (yield 0.4%). Last ex-dividend date: May 27, 2026. The P/E ratio is 35.1. The average price target of 18 analysts is ¥71.64.
Data as of November 22, 2026
Jiangsu Hengrui Pharmaceuticals compared with similar companies
Jiangsu Hengrui Pharmaceuticals's P/E (trailing 12 months): 35.1, −15% against the median of a group of 11 similar companies (41.2).
| Metric | Jiangsu Hengrui Pharmaceuticals | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 35.1 | 41.2 | 26.8 – 83.7 | Middle |
| Forward P/E | 30.9 | 30.9 | 23.6 – 50.6 | Middle |
| EV/EBITDA | 27.5 | 24.6 | 17.9 – 39.4 | Middle |
| Price/book | 4.64 | 4.64 | 3.35 – 11.9 | Middle |
| Price/sales | 9.50 | 9.50 | 4.06 – 14.2 | Middle |
| Gross margin | 86.4% | 75.9% | 64.1% – 84.0% | High |
| Operating margin | 27.4% | 24.1% | 19.7% – 32.8% | Middle |
| Net margin | 27.0% | 17.8% | 13.0% – 32.2% | Middle |
| ROE | 13.9% | 15.2% | 13.5% – 19.8% | Middle |
| Debt/equity | 0.00 | 0.11 | 0.02 – 0.44 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Jiangsu Hengrui Pharmaceuticals: valuation over time
On the latest fiscal year's earnings (2025), Jiangsu Hengrui Pharmaceuticals's P/E today is 39.8, below the median of its last 10 fiscal years (62.1; between 41.3 and 93.8 from 2016 to 2025). Relative to earnings, the stock costs less than it used to. The dividend yield (0.4%) is above the median of the last 10 fiscal years (0.3%).
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| 2025 | ¥59.57 | ¥1.18 | 50.5 | ¥0.20 | 0.3% |
| 2024 | ¥45.90 | ¥1.00 | 45.9 | ¥0.20 | 0.4% |
| 2023 | ¥45.23 | ¥0.68 | 66.5 | ¥0.20 | 0.4% |
| 2022 | ¥38.53 | ¥0.61 | 63.2 | ¥0.16 | 0.4% |
| 2021 | ¥50.71 | ¥0.71 | 71.4 | ¥0.16 | 0.3% |
| 2020 | ¥92.88 | ¥0.99 | 93.8 | ¥0.17 | 0.2% |
| 2019 | ¥60.78 | ¥0.83 | 72.9 | ¥0.16 | 0.3% |
| 2018 | ¥30.53 | ¥0.64 | 47.8 | ¥0.13 | 0.4% |
| 2017 | ¥30.71 | ¥0.50 | 61.0 | ¥0.06 | 0.2% |
| 2016 | ¥16.88 | ¥0.41 | 41.3 | ¥0.05 | 0.3% |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- ¥311.95B
- Enterprise value
- ¥271.65B
- PEG
- 0.93
- EV/revenue
- 8.27
Profitability and growth
- ROA
- 7.8%
- Revenue growth (year over year)
- -14.5%
- Earnings growth (year over year)
- -14.6%
Financial health
- Total cash
- ¥38.84B
- Total debt
- ¥67.98M
- Current ratio
- 7.91
- Quick ratio
- 7.25
Dividends
- Annual dividend per share
- ¥0.20
- Dividend yield
- 0.4%
- Payout ratio
- 14.9%
- Ex-dividend date
- May 27, 2026
Analysts and estimates
- Average price target
- ¥71.64
- Median price target
- ¥70.55
- High price target
- ¥111.00
- Low price target
- ¥50.00
- Analysts with a price target
- 18
- Consensus
- Strong buy
- Forward EPS
- ¥1.52
- EPS estimate, current year
- ¥1.39
Shares and trading
- Beta
- 0.04
- Average volume
- 60.76M
- Shares outstanding
- 6.38B
- Float
- 3.73B
- Institutional ownership
- 11.2%
- Insider ownership
- 46.4%
